Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And the case to come back in a fortnight if the SP is affected negatively, to highlight how correct they were.
Sangijuelas1 With the companies avacta now have investing in their affimer platform it is obvious that this is a potential world leading company with affimers replacing antibodies.
Small time delays on the lft will be seen to be insignificant going forward.
I am not dismissing ISA investment. I just mean that I am still hold in ISA but sold up in dealing accounts so as to transfer cash to Isa.
You see Avacta as along term investment then, Sang? You're giving off the opposite impression
Sounds like you’ve answered your own question (again). It really sounds like you’re not certain of why you’re here. Suggest you and Wyn book a 2hr slot in a pub to discuss where you go from here - over a pint, natch.
Sang, you've just made the case to dump your ISA holding.
Ultimately, the elongated ‘end of Q1 target’ is to be accepted or sold.
Dismissing ISA investment does not make sense. People hold investment in tax efficient wrappers, regardless of the risk profile.
If your immediate risk is too high, sell.
I have Wyn filtered as I think charts are a waste of time when it comes to investing long term in small cap stocks.
sell the rest, I would...
If I have a gripe it's that everyone says don't worry if the LFT falls down. There's the cancer treatments as if these will just be magically approved without delays or other issues.
There are so many investment opportunities out there it is a shame to get tied down to one based on assumptions about the future that are not sufficiently interrogated for their validity.
If you want some reassurance, perhaps ask Wyndrum for his opinion ;)
I said I sold 25% of my holding. I still have in Sipp as I can afford to wait there. The ISA holding is debatable.
The company has a lot going for it. It could also be a TO target. But at the moment it's all about the LFT as despite the potential acceleration of approval towards the end of the AVA6000 that doesn't offer cover for delays getting going.
"My issue is that I am not going to wait around expecting AVA6000 deadlines to be met by a company that has continually missed deadlines."
No one is forcing you to be invested, I would sell if I was as concerned as you.
But correlating the delays to innova’s process is not valid.
The delays are frustrating, but having a view of ‘just get a test out’ is not befitting of the future of the company. The test needs to be the best it can be.
We’re all hoping and believing our performance will shatter the current market leaders, so appreciate that takes time.
I don’t think so. Who knows how they managed to ge CE marked but the way we’re using them now (home self-testing) is not what they were designed to do. In the absence of a better test, it’s all the government can offer.
The best thing everyone can do is take the tests and upload their results onto the website, demonstrating adoption of the process at least. Which is why I’ll be doing exactly that rather than burning / binning them as some posters here have suggested!
Well they are expecting delays hence them flagging it up in the Feb RNS
Did Innova require the samples Avacta do?
Apologies for being crass, but innova’s test design, therefore testing and validation, is totally different to ours.
Yeah Mikey but I have held and accumulated 4D since 2017. I have interrogated my investment decision there many times and have kept coming back to the conclusion that its a hold
They were valued at £10 a share before I invested with a market cap of about £650m. Based on nothing but hot air. They have since progressed through clinical trials with positive results and are worth much less.
When I interrogate my investment decision here I get doubts that are not easily resolved. I sold out 25% on Friday as there seems to be a massive problem with getting clinical samples.
Did Innova have this problem?
Sang, I get the impression Avacta have a lot more control over the AVA6000 project compacted to the LFTS. I don't expect delays for AVA6000.
Sang totally agree, waiting for AVA we could be well into 2030 based on their track record. It's all about the lft for me and I will keep some in for the long term, as I'm sure we will be a hot takeover target. Many will sell for £5 or £10 by summer and come back later for AVA I think.
100% definitely we will be dosing patients and all targets will be met. Because that’s what happens in new drug trials...
I’m guessing you’re a part of that 30%
I am not saying 4D is a better company as they are very different.
My issue is that I am not going to wait around expecting AVA6000 deadlines to be met by a company that has continually missed deadlines.
That's a bit like sticking with an abusive partner expecting them to change whilst being gaslighted at the same time.
Because 4D is massively undervalued.
30% of the shares are held by loose fingered retail investors who haven't really got a clue.
The point is that they get on and launch trials more or less within the scheduled time frames.
I am doubtful that Avacta will be able to progress trials in a timely fashion and part of the problem is the reliance on NHS resources.
So
Why isn't that reflected in 4Ds share price?
And I am talking as a holder both there and here where I am much further up.